Citi Pharma Statistics

Total Valuation

Citi Pharma has a market cap or net worth of PKR 20.97 billion. The enterprise value is 21.58 billion.

Market Cap	20.97B
Enterprise Value	21.58B

Important Dates

The next estimated earnings date is Tuesday, April 29, 2025.

Earnings Date	Apr 29, 2025
Ex-Dividend Date	Oct 17, 2024

Share Statistics

Citi Pharma has 228.46 million shares outstanding. The number of shares has increased by 0.01% in one year.

Current Share Class	n/a
Shares Outstanding	228.46M
Shares Change (YoY)	+0.01%
Shares Change (QoQ)	+0.21%
Owned by Insiders (%)	52.11%
Owned by Institutions (%)	12.07%
Float	101.56M

Valuation Ratios

The trailing PE ratio is 25.50.

PE Ratio	25.50
Forward PE	n/a
PS Ratio	1.59
PB Ratio	3.92
P/TBV Ratio	3.92
P/FCF Ratio	223.45
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.06, with an EV/FCF ratio of 230.04.

EV / Earnings	26.26
EV / Sales	1.64
EV / EBITDA	15.06
EV / EBIT	16.83
EV / FCF	230.04

Financial Position

The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.34.

Current Ratio	1.24
Quick Ratio	0.59
Debt / Equity	0.34
Debt / EBITDA	1.25
Debt / FCF	19.17
Interest Coverage	4.45

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	22.96%
Revenue Per Employee	25.42M
Profits Per Employee	1.58M
Employee Count	519
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +273.53% in the last 52 weeks. The beta is 0.59, so Citi Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.59
52-Week Price Change	+273.53%
50-Day Moving Average	93.18
200-Day Moving Average	54.69
Relative Strength Index (RSI)	40.57
Average Volume (20 Days)	4,213,768

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Citi Pharma had revenue of PKR 13.19 billion and earned 821.88 million in profits. Earnings per share was 3.60.

Revenue	13.19B
Gross Profit	1.68B
Operating Income	1.28B
Pretax Income	1.26B
Net Income	821.88M
EBITDA	1.43B
EBIT	1.28B
Earnings Per Share (EPS)	3.60

Full Income Statement

Balance Sheet

The company has 1.18 billion in cash and 1.80 billion in debt, giving a net cash position of -618.18 million or -2.71 per share.

Cash & Cash Equivalents	1.18B
Total Debt	1.80B
Net Cash	-618.18M
Net Cash Per Share	-2.71
Equity (Book Value)	5.35B
Book Value Per Share	23.41
Working Capital	1.67B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 519.51 million and capital expenditures -425.69 million, giving a free cash flow of 93.83 million.

Operating Cash Flow	519.51M
Capital Expenditures	-425.69M
Free Cash Flow	93.83M
FCF Per Share	0.41

Full Cash Flow Statement

Margins

Gross margin is 12.75%, with operating and profit margins of 9.72% and 6.23%.

Gross Margin	12.75%
Operating Margin	9.72%
Pretax Margin	9.57%
Profit Margin	6.23%
EBITDA Margin	10.85%
EBIT Margin	9.72%
FCF Margin	0.71%

Dividends & Yields

This stock pays an annual dividend of 3.25, which amounts to a dividend yield of 3.73%.

Dividend Per Share	3.25
Dividend Yield	3.73%
Dividend Growth (YoY)	30.00%
Years of Dividend Growth	3
Payout Ratio	90.37%
Buyback Yield	-0.01%
Shareholder Yield	3.72%
Earnings Yield	3.92%
FCF Yield	0.45%

Dividend Details

Stock Splits

The last stock split was on October 18, 2021. It was a forward split with a ratio of 1.1.

Last Split Date	Oct 18, 2021
Split Type	Forward
Split Ratio	1.1

Scores

Citi Pharma has an Altman Z-Score of 2.33. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.33
Piotroski F-Score	n/a